Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07509086 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia

Name: IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia — clinical trial record (NCT07509086)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorThe First Hospital of Jilin University

Started2025-12-29

View on ClinicalTrials.gov ↗

The First Hospital of Jilin University

86 trials monitored

See 2 trials at risk

Leukemia

2,553 trials monitored

See 134 trials at risk

Multiple Myeloma

1,228 trials monitored

See 75 trials at risk

This is an open-label, single-arm, Phase 2 study to evaluate the efficacy and safety of IL-15-armored chimeric antigen receptor T-cell (CAR-T) therapy in subjects with relapsed or refractory multiple myeloma and plasma cell leukemia.

Trial Details

NCT Number	NCT07509086
Lead Sponsor	The First Hospital of Jilin University
Conditions	Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia (PCL)
Enrollment	25 participants
Start Date	2025-12-29
Primary Completion	2028-07-15 (estimated)
Study Completion	2029-07-15 (estimated)
Updated on ClinicalTrials.gov	2026-04-03